羟保松
| 中文名称 | 羟保松 |
|---|---|
| 中文同义词 | 羟保松;羟布宗;羟基保泰松;羟基保泰松,坦特利尔,羟保松;羟基保泰松溶液,100PPM;化合物 T16419;化合物:Oxyphenbutazone;羟基保泰松[SML0540] |
| 英文名称 | OXYPHENYL BUTAZONE |
| 英文同义词 | LABOTEST-BB LT00134684;OXYPHENYL BUTAZONE;1-(p-Hydroxyphenyl)-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine;1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione;1-(p-hydroxyphenyl)-2-phenyl-4-butylpyrazolidine-3,5-dione;1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine;1-phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-n-butylpyrazolidine;1-p-hydroxyphenyl-2-phenyl-3,5-dioxo-4-n-butylpyrazolidine |
| CAS号 | 129-20-4 |
| 分子式 | C19H20N2O3 |
| 分子量 | 324.37 |
| EINECS号 | 204-936-2 |
| 相关类别 | 抗炎镇痛药物;Active Pharmaceutical Ingredients;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals |
| Mol文件 | 129-20-4.mol |
| 结构式 |  |
羟保松 性质
| 熔点 | 109-111°C |
|---|---|
| 沸点 | 462.71°C (rough estimate) |
| 密度 | 1.2118 (rough estimate) |
| 折射率 | 1.6140 (estimate) |
| 储存条件 | -20°C |
| 溶解度 | DMSO：可溶10mg/mL，澄清 |
| 酸度系数(pKa) | pKa 4.7/10.0±0.2(H2O,t =25,Iundefined) (Uncertain) |
| 形态 | 粉末 |
| 颜色 | 白色至棕色 |
| 水溶解性 | 20mg/L(room temperature) |
| 稳定性 | 吸湿性 |
| InChI | 1S/C19H20N2O3/c1-2-3-9-17-18(23)20(14-7-5-4-6-8-14)21(19(17)24)15-10-12-16(22)13-11-15/h4-8,10-13,17,22H,2-3,9H2,1H3 |
| InChIKey | HFHZKZSRXITVMK-UHFFFAOYSA-N |
| SMILES | N2(N(C(=O)C(C2=O)CCCC)c3ccccc3)c1ccc(cc1)O |
| CAS 数据库 | 129-20-4(CAS DataBase Reference) |
| (IARC)致癌物分类 | 3 (Vol. 13, Sup 7) 1987 |
| EPA化学物质信息 | 3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl- (129-20-4) |
Oxyphenbutazone 是一种苯丁酮衍生物，具有抗炎作用。Oxyphenbutazone 是一种非选择性的 COX 抑制剂。Oxyphenbutazone 能选择性地杀死不复制的结核分枝杆菌。
COX
Oxyphenbutazone enhances the anticancer efficiency of methotrexate (MTX) in Hep3B cells.
Oxyphenbutazone (2.5 -7.5 µM; 48 hours) co-treatment with (MTX, 0.25-1.0 µM) shows potential cytotoxicity against Hep3B cells.
Oxyphenbutazone exhibits reparative effects in the hepatocytes.
Cell Cytotoxicity Assay
| Cell Line: | Hep3B cells |
| Concentration: | 2.5 µM, 5 µM, 7.5 µM |
| Incubation Time: | 48 hours |
| Result: | Enhanced the cytotoxicity of MTX. |
Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.).
| Animal Model: | 5–6 weeks Wistar strain albino male rats (150–220 g) |
| Dosage: | 70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week) |
| Administration: | Oral administration; once a week; in two divided doses; for 13 weeks |
| Result: | Exerted potential anticancer activity in rats when co-treatment with MTX. |
化学性质
白色结晶或结晶性粉末。熔点124-125℃。易溶于乙醇、丙酮，溶于氯仿、苯、醚，不溶于水。易溶于氢氧化碳或碳酸碱溶液。无臭，味苦。用途
用于治疗痛风、关节炎、风湿性或类风湿性关节炎及关节强硬性脊椎炎等。安全信息
| 危险品标志 | Xn,N |
|---|---|
| 危险类别码 | 22-50 |
| 安全说明 | 61 |
| 危险品运输编号 | UN 3077 9 / PGIII |
| WGK Germany | 3 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经口 危害水生环境-急性危害 类别1 |
| 毒害物质数据 | 129-20-4(Hazardous Substances Data) |